Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 5/20 | 0.66 |
| ▸ | CA1 | P00915 | 5/20 | 0.66 |
| ▸ | CA2 | P00918 | 5/20 | 0.66 |
| ▸ | CA9 | Q16790 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488414 | 0.96 | CA12 (0.67) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL30325046 | 0.92 | CA12 (0.57) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL30325282 | 0.92 | CA12 (0.57) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL15856108 | 0.92 | CA12 (0.67) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL17162046 | 0.90 | CA12 (0.61) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL5152100 | 0.89 | CA12 (0.66) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL445487 | 0.87 | CA1 (0.64) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL17675706 | 0.87 | CA12 (0.67) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL21068676 | 0.86 | CA12 (0.66) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL4954650 | 0.86 | CA12 (0.55) | TSHRMAPK1USP2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2019189419-A1 | ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| EP-1753736-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| EP-0760658-B1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0760658-A4 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0760658-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO. INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | TSHR 2428/4885MAPK1 1674/4885USP2 2885/4885 |
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | TSHR 3864/4885MAPK1 3999/4885USP2 223/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | TSHR 2833/4885MAPK1 1338/4885USP2 3025/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | TSHR 2428/4885MAPK1 1674/4885USP2 2885/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | TSHR 3864/4885MAPK1 3999/4885USP2 223/4885 |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | TSHR 3864/4885MAPK1 3999/4885USP2 223/4885 |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | TSHR 3864/4885MAPK1 3999/4885USP2 223/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | TSHR 2494/4885MAPK1 1636/4885USP2 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.